Attend the FierceBiotech Drug Development Forum
The leading executive-level forum for biotech strategy & networking | Oct 28-29 | Boston
Celtic Pharma has announced a new, $300 million pharmaceutical investment fund. Article
The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.
The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.
GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.